Literature DB >> 25503955

Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders.

Djillali Annane1, David Orlikowski, Sylvie Chevret.   

Abstract

BACKGROUND: Chronic alveolar hypoventilation is a common complication of many neuromuscular and chest wall disorders. Long-term nocturnal mechanical ventilation is commonly used to treat it. This is a 2014 update of a review first published in 2000 and previously updated in 2007.
OBJECTIVES: To examine the effects on mortality of nocturnal mechanical ventilation in people with neuromuscular or chest wall disorders. Subsidiary endpoints were to examine the effects of respiratory assistance on improvement of chronic hypoventilation, sleep quality, hospital admissions and quality of life. SEARCH
METHODS: We searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE and EMBASE on 10 June 2014. We contacted authors of identified trials and other experts in the field. SELECTION CRITERIA: We searched for quasi-randomised or randomised controlled trials of participants of all ages with neuromuscular or chest wall disorder-related stable chronic hypoventilation of all degrees of severity, receiving any type and any mode of long-term nocturnal mechanical ventilation. The primary outcome measure was one-year mortality and secondary outcomes were unplanned hospital admission, short-term and long-term reversal of hypoventilation-related clinical symptoms and daytime hypercapnia, improvement of lung function and sleep breathing disorders. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodology to select studies, extract data and assess the risk of bias in included studies. MAIN
RESULTS: The 10 eligible trials included a total of 173 participants. Roughly half of the trials were at low risk of selection, attrition or reporting bias, and almost all were at high risk of performance and detection bias. Four trials reported mortality data in the long term. The pooled risk ratio (RR) of dying was 0.62 (95% confidence interval (CI) 0.42 to 0.91, P value = 0.01) in favour of nocturnal mechanical ventilation compared to spontaneous breathing. There was considerable and significant heterogeneity between the trials, possibly related to differences between the study populations. Information on unplanned hospitalisation was available from two studies. The corresponding pooled RR was 0.25 (95% CI 0.08 to 0.82, P value = 0.02) in favour of nocturnal mechanical ventilation. For most of the outcome measures there was no significant long-term difference between nocturnal mechanical ventilation and no ventilation. Most of the secondary outcomes were not assessed in the eligible trials. Three out of the 10 trials, accounting for 39 participants, two with a cross-over design and one with two parallel groups, compared volume- and pressure-cycled non-invasive mechanical ventilation in the short term. From the only trial (16 participants) on parallel groups, there was no difference in mortality (one death in each arm) between volume- and pressure-cycled mechanical ventilation. Data from the two cross-over trials suggested that compared with pressure-cycled ventilation, volume-cycled ventilation was associated with less sleep time spent with an arterial oxygen saturation below 90% (mean difference (MD) 6.83 minutes, 95% CI 4.68 to 8.98, P value = 0.00001) and a lower apnoea-hypopnoea (per sleep hour) index (MD -0.65, 95% CI -0.84 to -0.46, P value = 0.00001). We found no study that compared invasive and non-invasive mechanical ventilation or intermittent positive pressure versus negative pressure ventilation. AUTHORS'
CONCLUSIONS: Current evidence about the therapeutic benefit of mechanical ventilation is of very low quality, but is consistent, suggesting alleviation of the symptoms of chronic hypoventilation in the short term. In four small studies, survival was prolonged and unplanned hospitalisation was reduced, mainly in participants with motor neuron diseases. With the exception of motor neuron disease and Duchenne muscular dystrophy, for which the natural history supports the survival benefit of mechanical ventilation against no ventilation, further larger randomised trials should assess the long-term benefit of different types and modes of nocturnal mechanical ventilation on quality of life, morbidity and mortality, and its cost-benefit ratio in neuromuscular and chest wall diseases.

Entities:  

Mesh:

Year:  2014        PMID: 25503955      PMCID: PMC7068159          DOI: 10.1002/14651858.CD001941.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  58 in total

1.  Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases.

Authors:  D Annane; M A Quera-Salva; F Lofaso; J B Vercken; O Lesieur; C Fromageot; B Clair; P Gajdos; J C Raphael
Journal:  Eur Respir J       Date:  1999-01       Impact factor: 16.671

Review 2.  Long-term home mechanical ventilation in the United States.

Authors:  Angela C King
Journal:  Respir Care       Date:  2012-06       Impact factor: 2.258

3.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

4.  Autotitrating versus standard noninvasive ventilation: a randomised crossover trial.

Authors:  J Jaye; M Chatwin; M Dayer; M J Morrell; A K Simonds
Journal:  Eur Respir J       Date:  2009-03       Impact factor: 16.671

5.  Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial.

Authors:  A C Pinto; T Evangelista; M Carvalho; M A Alves; M L Sales Luís
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

6.  Bringing the hospital home. Ethical and social implications of high-tech home care.

Authors:  J D Arras; N N Dubler
Journal:  Hastings Cent Rep       Date:  1994 Sep-Oct       Impact factor: 2.683

7.  Efficacy and comfort of volume-guaranteed pressure support in patients with chronic ventilatory failure of neuromuscular origin.

Authors:  Grazia Crescimanno; Oreste Marrone; Andreaw Vianello
Journal:  Respirology       Date:  2011-05       Impact factor: 6.424

8.  Comparison of noninvasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure.

Authors:  T Celikel; M Sungur; B Ceyhan; S Karakurt
Journal:  Chest       Date:  1998-12       Impact factor: 9.410

9.  Randomised trial of preventive nasal ventilation in Duchenne muscular dystrophy. French Multicentre Cooperative Group on Home Mechanical Ventilation Assistance in Duchenne de Boulogne Muscular Dystrophy.

Authors:  J C Raphael; S Chevret; C Chastang; F Bouvet
Journal:  Lancet       Date:  1994-06-25       Impact factor: 79.321

10.  Night-time nasal ventilation in neuromuscular disease.

Authors:  J Z Heckmatt; L Loh; V Dubowitz
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

View more
  23 in total

1.  Accuracy of tidal volume delivered by home mechanical ventilation during mouthpiece ventilation: A bench evaluation.

Authors:  Adam Ogna; Helene Prigent; Line Falaize; Karl Leroux; Dante Santos; Isabelle Vaugier; David Orlikowski; Frederic Lofaso
Journal:  Chron Respir Dis       Date:  2016-07-08       Impact factor: 2.444

Review 2.  Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Louisa Ng; Fary Khan; Carolyn A Young; Mary Galea
Journal:  Cochrane Database Syst Rev       Date:  2017-01-10

Review 3.  Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Authors:  Luis Garegnani; Martin Hyland; Pablo Roson Rodriguez; Camila Micaela E Escobar Liquitay; Juan Va Franco
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

Review 4.  Cardiovascular Disease in Duchenne Muscular Dystrophy: Overview and Insight Into Novel Therapeutic Targets.

Authors:  Taylor I Schultz; Frank J Raucci; Fadi N Salloum
Journal:  JACC Basic Transl Sci       Date:  2022-03-09

Review 5.  Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Authors:  Luis Garegnani; Martin Hyland; Pablo Roson Rodriguez; Camila Micaela Escobar Liquitay; Juan Va Franco
Journal:  Cochrane Database Syst Rev       Date:  2021-12-01

6.  Liberation and mortality outcomes in pediatric long-term ventilation: A qualitative systematic review.

Authors:  Candice M Foy; Monica L Koncicki; Jeffrey D Edwards
Journal:  Pediatr Pulmonol       Date:  2020-08-12

Review 7.  Nocturnal hypoventilation in neuromuscular disease: prevalence according to different definitions issued from the literature.

Authors:  Adam Ogna; Maria-Antonia Quera Salva; Helene Prigent; Ghassane Mroue; Isabelle Vaugier; Djillali Annane; Frederic Lofaso; David Orlikowski
Journal:  Sleep Breath       Date:  2015-09-04       Impact factor: 2.816

Review 8.  Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders.

Authors:  Fang Luo; Djillali Annane; David Orlikowski; Li He; Mi Yang; Muke Zhou; Guan J Liu
Journal:  Cochrane Database Syst Rev       Date:  2017-12-04

Review 9.  Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Aleksandar Radunovic; Djillali Annane; Muhammad K Rafiq; Ruth Brassington; Naveed Mustfa
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06

10.  Natural History of Cardiac and Respiratory Involvement, Prognosis and Predictive Factors for Long-Term Survival in Adult Patients with Limb Girdle Muscular Dystrophies Type 2C and 2D.

Authors:  Abdallah Fayssoil; Adam Ogna; Cendrine Chaffaut; Sylvie Chevret; Raquel Guimarães-Costa; France Leturcq; Karim Wahbi; Helene Prigent; Frederic Lofaso; Olivier Nardi; Bernard Clair; Anthony Behin; Tanya Stojkovic; Pascal Laforet; David Orlikowski; Djillali Annane
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.